Threshold examples (e.g., GLS ↓ ≥ 15%, LVEF ↓ ≥ 10 points to <50%, marked QTc prolongation, persistent hs-troponin/NT-proBNP elevation) align with widely adopted clinical signals; precise weights and cut points require prospective calibration and external validation across tumor types, regimens, and health-system settings. The gene discussed is NPPB; the disease is neoplasm.